Furthermore, survival analysis of primary GBM samples demonstrated that patient groups expressing higher levels of SV2B in comparison to those with lower expression levels had significantly shorter overall survival and disease specific survival (p < 0.01119 and p < 0.02197, respectively) (Fig. 3e,f). This evidence concerns the gene SV2B and glioblastoma.